or Try an Advanced Search...

    Technical Analysis for AMAM - Ambrx Biopharma Inc.

    Grade Last Price % Change Price Change
    B 11.20 2.75% 0.30
    AMAM closed up 2.75 percent on Thursday, September 28, 2023, on 1.11 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    3 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Up
    Historical AMAM trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    NR7-2 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Gapped Up Strength 0.00%
    MACD Bullish Signal Line Cross Bullish 2.75%
    NR7 Range Contraction 2.75%
    NR7-2 Range Contraction 2.75%
    Wide Bands Range Expansion 2.75%
    NR7 Range Contraction 5.76%
    NR7-2 Range Contraction 5.76%
    Older End-of-Day Signals for AMAM ...

       Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

    Alert Time
    Possible NR7 about 9 hours ago
    60 Minute Opening Range Breakdown about 12 hours ago
    Down 1% about 12 hours ago
    Fell Below 10 DMA about 12 hours ago
    10 DMA Support about 13 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    AMAM Chart by TradingView
    Basic chart:

    Profile

    Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788. In addition, the company has clinical collaborations with Bristol Myers Squibb, Astellas, BeiGene, Sino Biopharma, Elanco and NovoCodex, for drug candidates generated using Ambrx technology.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Immunology Health Sciences Pharmacy Cancer Immunotherapy Antibody Drug Conjugate Oncology Therapies Beigene

    Is AMAM a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Sep 26 Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023
    Sep 20 Ambrx Biopharma says Cormorant Asset Management buys 2.15M shares
    Sep 20 Around $19M Bet On Westrock Coffee? Check Out These 3 Stocks Insiders Are Buying
    Sep 18 Ambrx to Participate in the Cantor Fitzgerald Global Healthcare Conference
    Sep 5 Ambrx to Present at the Baird and Morgan Stanley Global Healthcare Conferences
    Aug 21 Promising Developments In Ambrx's Engineered Precision Biologics
    Aug 11 RBC Predicts 100% Gains for These 2 Stocks — Here’s Why They Have Strong Upside
    Aug 1 Ambrx Appoints Renu Vaish, M.Sc., as Chief Regulatory Officer to Lead Regulatory Affairs
    Jul 28 Ambrx to Present Preliminary ARX517 First-in-Human Safety, Efficacy, and Pharmacokinetics Data at ESMO 2023
    Jul 19 Ambrx prostate cancer candidate granted Fast Track status
    See more AMAM news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.86
    52 Week Low 0.38
    Average Volume 395,931
    200-Day Moving Average 9.83
    50-Day Moving Average 13.32
    20-Day Moving Average 11.69
    10-Day Moving Average 10.91
    Average True Range 0.93
    RSI (14) 43.18
    ADX 19.22
    +DI 19.32
    -DI 26.95
    Chandelier Exit (Long, 3 ATRs) 12.40
    Chandelier Exit (Short, 3 ATRs) 11.11
    Upper Bollinger Bands 14.30
    Lower Bollinger Band 9.08
    Percent B (%b) 0.41
    BandWidth 44.65
    MACD Line -0.73
    MACD Signal Line -0.79
    MACD Histogram 0.0566
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 12.01
    Resistance 3 (R3) 11.93 11.59 11.88
    Resistance 2 (R2) 11.59 11.38 11.63 11.83
    Resistance 1 (R1) 11.39 11.25 11.49 11.47 11.78
    Pivot Point 11.05 11.05 11.10 11.09 11.05
    Support 1 (S1) 10.85 10.84 10.95 10.93 10.62
    Support 2 (S2) 10.51 10.71 10.55 10.57
    Support 3 (S3) 10.31 10.51 10.53
    Support 4 (S4) 10.39